硫酸氨基葡萄糖联合美洛昔康对膝骨关节炎患者血清FGF-2、TGF-β、IGF-1水平及膝关节运动功能的影响  

Effects of Glucosamine Sulfate Combined with Meloxicam on Serum FGF⁃2,TGF⁃β,IGF⁃1 Levels and Knee Motor Function in Patients with Knee Osteoarthritis

作　　者：胡科迪 刘凯 HU Kedi;LIU Kai(Department of Trauma,Daxing Hospital of Capital Medical University,Beijing 102600,China)

机构地区：[1]首都医科大学大兴医院创伤科,北京102600

出　　处：《临床误诊误治》2024年第9期66-70,共5页Clinical Misdiagnosis & Mistherapy

基　　金：国家卫生健康委“十四五”规划全国重点课题(YYWS5228)。

摘　　要：目的 探究硫酸氨基葡萄糖联合美洛昔康对膝骨关节炎患者血清成纤维细胞生长因子-2(fibroblast growth factor-2, FGF-2)、转化生长因子-β(transforming growth factor-β, TGF-β)、胰岛素样生长因子-1(insulin-like growth factor-1, IGF-1)水平及膝关节运动功能的影响。方法 选择2021年6月-2023年6月就诊的膝骨关节炎114例,以随机数字表法分为联合组和美洛昔康组各57例。美洛昔康组予美洛昔康片治疗,联合组在美洛昔康组基础上加用硫酸氨基葡萄糖胶囊治疗,均治疗6周后观察疗效,比较2组治疗前、治疗6周后膝关节运动功能、炎性因子、生长因子水平及治疗期间安全性。结果 治疗6周后,联合组总有效率为91.23%(52/57)高于美洛昔康组的73.68%(42/57)(P<0.05)。治疗6周后,2组5次坐立试验、2.4 m起立行走试验所需时间短于治疗前,且联合组短于美洛昔康组(P<0.05,P<0.01);西安大略和麦克马斯特大学骨关节炎指数评分及血清前列腺素E2、白细胞介素-17、基质金属蛋白酶-3水平低于治疗前,且联合组低于美洛昔康组(P<0.05,P<0.01)。治疗6周后,2组血清FGF-2、TGF-β、IGF-1水平均高于治疗前,且联合组高于美洛昔康组(P<0.05,P<0.01)。2组治疗期间总不良反应发生率比较差异无统计学意义(P>0.05)。结论 硫酸氨基葡萄糖联合美洛昔康可有效升高膝骨关节炎患者血清FGF-2、TGF-β、IGF-1水平,延缓软骨退行性病变,控制机体炎症反应,进而有效改善患者膝关节运动功能,疗效显著,安全性良好。Objective To investigate the effects of Glucosamine Sulfate combined with Meloxicam on the levels of se-rum fibroblast growth factor-2(FGF-2),transforming growth factor-β(TGF-β),insulin-like growth factor-1(IGF-1)and knee motor function in patients with knee osteoarthritis(KOA).Methods A total of 114 patients with KOA were selected from June 2021 to June 2023 and divided into the combination group(n=57)and Meloxicam group(n=57)by random number table method.The Meloxicam group was treated with Meloxicam tablets,and the combination group was supplemented with Glucosamine Sulfate capsules based on the Meloxicam group for 6 weeks.The therapeutic effect of the two groups at 6 weeks after treatment was observed,and the knee joint motor function indexes,inflammatory factors,growth factors levels and safety during treatment were compared between the two groups before and at 6 weeks after treatment.Results At 6 weeks after treatment,the total effective rate of combination group was 91.23%(52/57),which was higher than that of Meloxicam group[73.68%(42/57)](P<005).At 6 weeks after treatment,the time required for 5 times sit-to-stand(5-STS)test and 2.4 m Timed Up and Go(TUG)test in the two groups was shorter than that before treatment,which was shorter in the combination group than the Meloxicam group(P<005,P<001).Western Ontario and McMaster University osteoarthritis index scores and serum prostaglandin E2,interleukin-17,matrix metalloproteinase-3 levels were lower than those before treatment,which were lower in the combination group than in the Meloxicam group(P<005,P<001).At 6 weeks after treatment,the serum levels of FGF-2,TGF-βand IGF-1 in the two groups were higher than those before treatment,which were higher in the combina-tion group than in the Meloxicam group(P<005,P<001).There was no significant difference in the incidence of adverse reactions between the two groups(P>005).Conclusion Glucosamine Sulfate combined with Meloxicam can effectively in-crease the levels of serum FGF-2,TGF-βand IGF-1 in patients with

关 键 词：膝骨关节炎 硫酸氨基葡萄糖 美洛昔康 西安大略和麦克马斯特大学骨关节炎指数 成纤维细胞生长因子-2 转化生长因子-β 胰岛素样生长因子-1 药物毒性 

分 类 号：R684.3[医药卫生—骨科学]